A Single-blind, Randomized, Controlled Clinical Study of Flash Stimulation Therapy in Parkinson's Disease

Prior treatment

• Alcohol, coffee, or drug abusers in the past 6 months;
• Used drugs or health products that regulate sleep function or affect sleep within 14 days before enrollment or less than 5 drug half-lives;
• Taking drugs that may impair cognitive ability, such as anticholinergic drugs, memory enhancing drugs, etc., within 7 days before enrollment;

Other illness

• Secondary insomnia: including sleep disorders (restless leg syndrome, periodic limb movement disorder, sleep-related breathing disorders, etc.), physical diseases, mental disorders, psychoactive substance abuse;
• suffering from photosensitive dermatitis, epilepsy and other diseases that are not suitable for flash stimulation;
• Mental illness: such as anxiety, depression, schizophrenia and post-traumatic stress disorder caused by insomnia;
• suffering from other neurodegenerative diseases;

Other

• the subject is unable to complete the test or follow-up;
• There are endoplants in the body that cannot be examined by MRI;
• Inability to lie flat;
• Other situations in which the researcher considers it inappropriate to participate in the study.

• PD patients who meet the diagnostic criteria of the International Movement Disorders Association (MDS), between the ages of 50 and 70 years, the course of disease ≤5 years, and the Hoehn \& Yahr stage ≤3;
• Anti-PD drugs were taken regularly for at least one month before screening, and symptoms were stable;
• The fixed bedtime in the past month is between 9:00 p.m. and 1:00 a.m., and the total sleep time is ≥6 hours;
• Have the ability to understand and voluntarily sign informed consent;
• Have good compliance and are willing to complete all follow-up required by this program.